Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early ropinirole prolonged-release plus rasagiline in newly diagnosed Parkinson's disease
2009-013004-31Phase 3Completed
- Sponsor
- University of Parma
- Start
- Nov 2009
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rasagiline and ropinirole in Parkinson's disease (PD) (2 arms), sponsored by University of Parma. Primary endpoints: Degree of motor impairment requiring levodopa therapy, UPDRS Part II threshold and 3 more. Started Nov 2009; status: completed.
02
Drugs
rasagilineropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-013004-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013004-31.